Efficacy News and Research

RSS

Phase 1 trial of COVID-19 PTXCOVID19-B vaccine

A new study demonstrated that the SARS-CoV-2 PTXCOVID19-B vaccine was a promising SARS-CoV-2 vaccine option.

12 May 2022

Study finds recent influenza vaccination is associated with an appreciable reduction in the risk of SARS-CoV-2 infection and COVID-19 severity

The current study was performed in Qatar, including over 30,000 healthcare workers vaccinated against influenza during the period between September 17, 2020, and December 31, 2020, when the annual flu shots are usually given.

12 May 2022

COVID-19 booster vaccination strategy found to be highly cost-effective in Australia

Researchers evaluated the cost-effectiveness of Australia’s COVID-19 booster vaccination strategy.

12 May 2022

Study projects the COVID-19 burden caused by Omicron infections in mainland China should the zero-COVID policy be lifted

A new paper describes a new epidemiological model of SARS-CoV-2 transmission that includes the burden of COVID-19, vaccination coverage, available antiviral therapies, and non-pharmaceutical interventions.

12 May 2022

Delta- and Omicron BA.1-variant specificity of B cell repertoires established by an initial Wuhan strain infection

Researchers performed an unbiased evaluation of the early memory B cell repertoire specific for the Omicron and Delta variants of SARS-CoV-2.

12 May 2022

Research looks at potential of pantethine against SARS-CoV-2

In a recent study posted to the Research Square preprint server, researchers assessed the antiviral activity of pantethine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

12 May 2022

Study estimates effectiveness of 2-dose and 3-dose mRNA vaccination against Omicron

In a recent study posted to the medRxiv* preprint server, researchers estimated the efficacy of two-dose and three-dose regimens of two messenger ribonucleic acid (mRNA) vaccines: Moderna’s mRNA-1273 and Pfizer-BioNTech’s BNT162b2 against coronavirus disease 2019 (COVID-19) caused due to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant.

12 May 2022

Antifungal agent Bifonazole as an antiviral against SARS-CoV-2

In a recent study published in the journal Molecular Therapy, researchers identified Bifonazole, an imidazole-based antifungal agent, to have potent activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using high-throughput screening of small molecules.

12 May 2022

The promise of RNA medicine is targeted and personalized

The development of messenger RNA (mRNA) vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has only increased the impetus in this field.

11 May 2022

Clemson researchers discover a promising therapy for people suffering from toxoplasmosis

Many doctors caution their pregnant patients to avoid cat feces; even the family pet's litter box is off-limits. Now, a group of researchers from Clemson University have discovered a promising therapy for those who suffer from toxoplasmosis, a disease caused by the microscopic protozoa Toxoplasma gondii.

11 May 2022

First oral antiviral approved for early treatment of COVID-19

The United States Food and Drug Administration granted an Emergency Use Authorization in December 2021 for the first oral antiviral, a pill containing two protease inhibitors – nirmatrelvir and ritonavir (Paxlovid, Pfizer) – for early treatment of COVID-19.

11 May 2022

Study shows efficacy of COVID-19 vaccine in people receiving cancer treatment

People undergoing active cancer treatment, including stem cell transplant, should receive the COVID-19 vaccine, according to a study published in JAMA Oncology.

11 May 2022

Effectiveness of COVID-19 monoclonal antibodies against SARS-CoV-2 Omicron variant

Researchers depicted the efficacy of the SARS-CoV-2 monoclonal antibodies (mAbs) against the SARS-CoV-2 Omicron variant.

11 May 2022

New classification by ESMO to guide research on treatment de-escalation in oncology

ESMO, the leading professional organization for medical oncology, has developed a new evidence-based classification to guide research and interpretation of data on treatment de-escalation in oncology.

11 May 2022

UCLouvain discovery could counter SARS-CoV-2 virus independently of the mutations

Despite the effectiveness of vaccination campaigns worldwide, the threat posed by Covid-19 still exists. First of all, a new SARS-CoV-2 variant could very well emerge that may not respond to current vaccines.

10 May 2022

Breastfeeding associated with improved maternal mental health outcomes

Scientists from the University of Massachusetts, USA, have recently found that breastfeeding is associated with improved maternal mental health overall.

10 May 2022

Heightened antibody responses in COVID-19 booster vaccinated individuals following SARS-CoV-2 Omicron

Investigators illustrated that a SARS-CoV-2 Omicron infection post-booster vaccination imparts robust, long-lasting immunity against future re-infections.

10 May 2022

mRNA boosters enhance neutralization of SARS-CoV-2 BA.1, BA.2 and BA.3

A study recently published in the journal Cell Host & Microbe has described that all three sublineages of the omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibit similar host cell entry efficiency and are neutralized equally by antibodies generated in response to coronavirus disease 2019 (COVID-19) booster vaccination

10 May 2022

Remdesivir shows no significant effect on patients with COVID-19 in Solidarity trial

A recent study published in the journal The Lancet summarized the final results of the Solidarity trial which aimed at finding out which drugs were most effective at reducing the severity of the disease among hospitalized patients.

9 May 2022

More evidence that pediatric COVID vaccination prevents MIS-C

Researchers designed a nationwide pediatric COVID-19 research project based on real-time data since the early phase of the pandemic.

9 May 2022

Efficacy News and Research

Phase 1 trial of COVID-19 PTXCOVID19-B vaccine

Study finds recent influenza vaccination is associated with an appreciable reduction in the risk of SARS-CoV-2 infection and COVID-19 severity

COVID-19 booster vaccination strategy found to be highly cost-effective in Australia

Study projects the COVID-19 burden caused by Omicron infections in mainland China should the zero-COVID policy be lifted

Delta- and Omicron BA.1-variant specificity of B cell repertoires established by an initial Wuhan strain infection

Research looks at potential of pantethine against SARS-CoV-2

Study estimates effectiveness of 2-dose and 3-dose mRNA vaccination against Omicron

Antifungal agent Bifonazole as an antiviral against SARS-CoV-2

The promise of RNA medicine is targeted and personalized

Clemson researchers discover a promising therapy for people suffering from toxoplasmosis

First oral antiviral approved for early treatment of COVID-19

Study shows efficacy of COVID-19 vaccine in people receiving cancer treatment

Effectiveness of COVID-19 monoclonal antibodies against SARS-CoV-2 Omicron variant

New classification by ESMO to guide research on treatment de-escalation in oncology

UCLouvain discovery could counter SARS-CoV-2 virus independently of the mutations

Breastfeeding associated with improved maternal mental health outcomes

Heightened antibody responses in COVID-19 booster vaccinated individuals following SARS-CoV-2 Omicron

mRNA boosters enhance neutralization of SARS-CoV-2 BA.1, BA.2 and BA.3

Remdesivir shows no significant effect on patients with COVID-19 in Solidarity trial

More evidence that pediatric COVID vaccination prevents MIS-C

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News